Trial
NCT00901927
Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
M.D. Anderson Cancer Center
Collaborators
Cephalon
Condition
Follicular Lymphoma
Intervention
Bendamustine
Why stopped
Study was closed early due to toxicity
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-04-03